	US 12,357,664 B2
	Optimized oncolytic viruses and uses thereof
Peter M. Chumakov, Solon, OH (US); Anastasia V. Lipatova, Moscow (RU); Stepan P. Chumakov, Moscow (RU); Natalia D. Tararova, Gates Mills, OH (US); Stephen A. Charles, Chagrin Falls, OH (US); and Anton A. Komar, Gates Mills, OH (US)
Assigned to SATOR THERAPEUTICS, Cleveland, OH (US)
Filed by Sator Therapeutics, Cleveland, OH (US)
Filed on Dec. 6, 2021, as Appl. No. 17/543,206.
Application 17/543,206 is a division of application No. 15/716,974, filed on Sep. 27, 2017, granted, now 11,253,558.
Claims priority of provisional application 62/426,724, filed on Nov. 28, 2016.
Claims priority of provisional application 62/400,310, filed on Sep. 27, 2016.
Prior Publication US 2022/0088097 A1, Mar. 24, 2022
Int. Cl. A61K 35/768 (2015.01); A61K 35/76 (2015.01); C12N 7/00 (2006.01); C12N 15/01 (2006.01); G01N 33/50 (2006.01)

CPC A61K 35/768 (2013.01) [A61K 35/76 (2013.01); C12N 7/00 (2013.01); C12N 15/01 (2013.01); G01N 33/5011 (2013.01); C12N 2770/32321 (2013.01); C12N 2770/32332 (2013.01); C12N 2770/32351 (2013.01); G01N 2333/085 (2013.01); Y02A 50/30 (2018.01)]

12 Claims

1. A method of generating a synthetic targeted virus for a cancer cell from a reference virus for a normal cell, comprising:

for each codon in a given position in the reference virus that codes for a given amino acid, identifying a codon frequency for each codon that codes for the given amino acid in the cancer cell;

selecting a codon for the given amino acid in the cancer cell that best corresponds to the codon in the reference virus;

using the selected codon for the given amino acid in the cancer cell in a location in the synthetic targeted virus that matches the given position in the reference virus.